This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
4 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.
ResMed (RMD) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Lower device sales including weak demand for ventilators due to COVID-19 hurt ResMed's (RMD) Q3 top line.
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Guidance Up
by Zacks Equity Research
Bio-Rad's (BIO) first-quarter revenues improved year over year on robust growth in Life Science and Clinical Diagnostics segments.
What's in Store for Fulgent Genetics' (FLGT) Q1 Earnings?
by Zacks Equity Research
COVID-19 testing and NGS-based testing solutions are expected to have contributed to Fulgent Genetics' (FLGT) Q1 earnings.
Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners
by Zacks Equity Research
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Zacks Rank.
Syneos Health (SYNH) Q1 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Syneos Health (SYNH) registers sales uptick in its Clinical Solutions business on the back of favorable acquisition impacts and increased project start-up activities.
Here's How Much You'd Have If You Invested $1000 in HCA Holdings a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Community Health (CYH) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Community Health's (CYH) first-quarter results reflect decline in operating and interest expenses, partly offset by weaker admissions.
Humana's (HUM) Q1 Earnings Surpass Estimates, Improve Y/Y
by Zacks Equity Research
Humana's (HUM) Q1 earnings gain from better revenues and a solid contribution by its Retail segment.
Encompass Health (EHC) Q1 Earnings Beat, Hikes '21 View
by Zacks Equity Research
Encompass Health's (EHC) first-quarter results reflect improved Inpatient Rehabilitation segment revenues, partly offset by lower volumes in both its segments and higher costs.
Centene (CNC) Q1 Earnings Miss Estimates, Hikes '21 View
by Zacks Equity Research
Centene's (CNC) first-quarter results reflect higher revenues and growing Medicare as well as Medicaid membership, partly offset by escalating costs.
Universal Health (UHS) Q1 Earnings Top, Revenues Improve Y/Y
by Zacks Equity Research
Universal Health's (UHS) first-quarter results highlight uptick in revenues across both the company's segments, partly offset by escalating costs.
Penumbra (PEN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growth across vascular thrombectomy and embolization products is expected to have contributed to Penumbra's (PEN) Q1 performance.
What's in Store for IDEXX Laboratories (IDXX) in Q1 Earnings?
by Zacks Equity Research
IDEXX (IDXX) first-quarter top line is expected to have benefited from strength in CAG and LPD businesses.
Avantor, Inc. (AVTR) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Avantor, Inc. (AVTR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
BioRad (BIO) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Growing demand for Polymerase Chain Reaction and Droplet Digital PCR products is expected to have contributed to BioRad's (BIO) Q1 growth.
Company News for Apr 23, 2021
by Zacks Equity Research
Companies In The News Are: T, HCA, CLF, TSCO
ResMed (RMD) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in demand for Mask and Other accessories along with rapid adoption of digital health solution is likely to have contributed to ResMed's (RMD) Q3 growth.
LabCorp (LH) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
With respect to LabCorp's (LH) COVID-19 testing services wing, although extensive vaccine rollouts are ongoing, the resurgence of the virus might have once again boosted testing demand in Q1.
Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings
by Zacks Equity Research
Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.
Integra (IART) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.
HCA Healthcare's (HCA) Q1 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
HCA Healthcare's (HCA) first-quarter results highlight higher revenues, partly offset by increased costs.
HCA Holdings (HCA) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
HCA (HCA) delivered earnings and revenue surprises of 23.58% and 2.19%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for HCA Healthcare (HCA) This Earnings Season?
by Zacks Equity Research
HCA Healthcare (HCA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid
by Zacks Equity Research
The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.